Dr. Christine Durand, assistant professor of medicine and oncology and member of the Johns Hopk...ins Kimmel Cancer Center, is involved in clinical and translational research focused on individuals infected with HIV and hepatitis C virus who require cancer and transplant therapies. Her current research efforts include looking at outcomes of hepatitis C treatment after solid organ transplant, the potential use of organs from HIV-infected donors for HIV-infected solid organ transplant candidates, and HIV cure strategies including bone marrow transplantation.

Dr. Durand is supported by multiple grants:

• R01 from the National Institute of Allergy and Infectious Diseases (NIAID) to study HIV-to-HIV organ transplantation in the US.
• K23 from the National Cancer Institute (NCI) to study antiretroviral therapy during bone marrow transplant in HIV-1 infection.
• U01 from the NIAID to study HIV-to-HIV deceased donor kidney transplantation.
U01 from the NIAID to study HIV-to-HIV deceased donor liver transplantation. view more

The Clinical Laboratory and Biomarkers Cores will coordinate access to laboratory expertise, te...sting, training, specimen repositories and Good Clinical Laboratory Practices (GCLP). The goals of this core are to assure that all JHU HIV investigators have access to and utilize appropriate, validated and, where applicable, certified laboratory assays. The core will also maintain a biomarker specimen repository for storage cataloguing and utilization of biological specimens. view more

Research in the Craig W. Hendrix Lab concentrates on the chemoprevention of HIV infection, clin...ical pharmacology of antiviral drugs, drug interactions, and oral, topical and injectable HIV microbicide development. Our lab conducts small, intensive sampling studies of PK and PD of drugs for HIV prevention with a focus on developing methods to better understand HIV and drug distribution in the male genital tract, female genital tract and lower gastrointestinal tract. We also support numerous HIV pre-exposure prophylaxis development studies from phase I to phase III, largely as leader of the Pharmacology Core Laboratory of both the Microbicide Trial Network and HIV Prevention Trials Network. view more

The David Graham Lab studies the consequences of HIV interactions with the immune system, the r...esulting pathogenesis and how to sabotage these interactions. We apply advanced technologies like mass spectrometry to dissect processes at the molecular level. We are also actively involved in cardiovascular research and studies the ways proteins are organized into functional units in different cell types of the heart.

Major projects in our lab are organized into three major areas: (1) H/SIV pathogenesis and neuropathogenesis, (2) Cardiovascular disease, and (3) High technology development
view more

The David Thomas Lab oversees clinical research projects that aim to understand the natural his...tory and pathogenesis of hepatitis C virus infection. A special area of clinical and research focus is liver disease in HIV-infected people. view more

Research in the Erica Johnson Lab investigates infection control in military deployment environ...ments as well as infections that are associated with combat trauma. We explore topics such as HIV outcomes, gender-based health issues and disparities in care. view more

The Gail Berkenblit Lab focuses on HIV testing. We are particularly interested in the training ...of residents as it relates to HIV outpatient care, and the development and assessment of online curriculum. view more

Research in the Gregory Kirk Lab examines the natural history of viral infections — particularl...y HIV and hepatitis viruses — in the U.S. and globally. As part of the ALIVE (AIDS Linked to the Intravenous Experience) study, our research looks at a range of pathogenetic, clinical behavioral issues, with a special focus on non-AIDS-related outcomes of HIV, including cancer and liver and lung diseases. We use imaging and clinical, genetic, epigenetic and proteomic methods to identify and learn more about people at greatest risk for clinically relevant outcomes from HIV, hepatitis B and hepatitis C infections. Our long-term goal is to translate our findings into targeted interventions that help reduce the disease burden of these infections. view more